Susan Perrine
Phoenicia BioScience · HemaQuest Pharmaceuticals
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Susan Perrine as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04432623 · The BENeFiTS Trial in Beta Thalassemia IntermediaPhoenicia BioScience · enrolling by invitation · Beta Thalassemia Intermedia, Sickle Cell Disease · study director
- Ph1/Ph2NCT00842088 · Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell DiseaseHemaQuest Pharmaceuticals Inc. · completed · Sickle Cell Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 15 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Development of a Clinical Hemoglobin ModulatorR33HL147845 · NHLBI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2020 to 2022 · $1,630,002 awarded in 2022Grant number is on one of their registry trials
- Virus-targeted therapeutic for EBV-Associated MalignanciesR44CA153474 · NCI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2016 to 2017 · $519,583 awarded in 2017Same name and institution; not confirmed by an ID
- Development of a clinical hemoglobin modulatorR42HL110727 · NHLBI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2014 to 2015 · $499,996 awarded in 2015Same name and institution; not confirmed by an ID
- Topical Therapeutic to Promote Healing of Chronic WoundsR41GM101869 · NIGMS · PHOENICIA BIOSCIENCES, INC. · fiscal years 2013 · $219,306 awarded in 2013Same name and institution; not confirmed by an ID
- Next Generation Therapeutics for HemoglobinopathiesR41HL108516 · NHLBI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2012 · $491,254 awarded in 2012Same name and institution; not confirmed by an ID
- in vivo Studies of Clinical Stage Globin ModulatorsR41HL110727 · NHLBI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2011 · $304,344 awarded in 2011Same name and institution; not confirmed by an ID
- Virus-Targeted Therapy for MalignanciesR43CA153474 · NCI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2011 · $288,895 awarded in 2011Same name and institution; not confirmed by an ID
- Oral Agents to Stimulate Neutrophil ProductionR41HL087542 · NHLBI · PHOENICIA BIOSCIENCES, INC. · fiscal years 2010 · $350,566 awarded in 2010Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:58 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.N Engl J Med · 1993443 citationsRCR 10.9
- 218 citationsRCR 4.9
- Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.Blood · 1999216 citationsRCR 4.5
- 75 citationsRCR 1.6
- A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers.Br J Haematol · 201048 citationsRCR 1.4
- A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia.Br J Haematol · 201332 citationsRCR 1.0
- A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.Am J Hematol · 201328 citationsRCR 0.9
- Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress.Ann N Y Acad Sci · 200525 citationsRCR 0.6
- 25 citationsRCR 0.8
- A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.Am J Hematol · 201225 citationsRCR 0.7